

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waivers under 18 U.S.C. § 208(b)(3) and 21 U.S.C. §355(n)(4)**

Neal Benowitz, M.D.

Committees: Joint Nonprescription Drugs Advisory Committee and Endocrinologic
and Metabolic Drugs Advisory Committee Meeting

Meeting Dates: January 23, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda items new drug application (NDA) 21-887, proposing over-the-counter (OTC) use of Orlistat (tetrahydrolipstatin) 60 milligram (mg) capsules, sponsored by GlaxoSmithKline Consumer Healthcare, L.P., an associate of GlaxoSmithKline PLC, to promote weight loss in overweight adults when used along with a reduced calorie and low fat diet, I am eligible to receive waivers under 18 U.S.C. § 208(b)(3) and 21 USC §355(n)(4).

Type of Interest	Nature	Magnitude
Consulting (advisory board on unrelated matter)	Competitor	Less than \$10,001 per year
Consulting (advisory board on unrelated matter)	Competitor	Less than \$10,001 per year
Consulting	Sponsor	Less than \$10,001 per year
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

Signature of SGE

12/22/05

Date